Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.27 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%.
Chugai Pharmaceutical Stock Performance
CHGCY opened at $21.79 on Tuesday. The company has a 50-day moving average of $20.75 and a 200-day moving average of $24.66. The company has a market capitalization of $71.72 billion, a P/E ratio of 23.68 and a beta of 0.60. Chugai Pharmaceutical has a 1-year low of $18.33 and a 1-year high of $34.84.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on CHGCY. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.
Get Our Latest Analysis on Chugai Pharmaceutical
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.
The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.
Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.
Read More
- Five stocks we like better than Chugai Pharmaceutical
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
